<DOC>
	<DOCNO>NCT00125970</DOCNO>
	<brief_summary>The purpose study determine safety immune response DNA HIV vaccine follow adenoviral vector HIV vaccine HIV uninfected adult .</brief_summary>
	<brief_title>Safety Immune Response DNA HIV Vaccine Followed By Adenoviral Vector HIV Vaccine Healthy Adults</brief_title>
	<detailed_description>The worldwide HIV/AIDS epidemic may control development safe effective vaccine prevent HIV infection . DNA vaccine inexpensive construct , readily produce large quantity , stable long periods time . This study evaluate safety immunogenicity experimental multiclade HIV vaccine , VRC-HIVDNA016-00-VP , follow similarly structure adenovirus-vectored vaccine boost , VRC-HIVADV014-00-VP , HIV uninfected adult . The DNA plasmid vaccine code protein HIV subtypes A , B , C , together represent 90 % new HIV infection world . Participants study recruit North America , South America , Africa . Each volunteer participate study 36 month . Participants randomly assign one two group . Group 1 participant receive DNA HIV vaccine study entry Months 1 2 . At Month 6 , Group 1 participant receive injection adenoviral vector HIV vaccine . Group 2 participant receive placebo study entry Months 1 , 2 , 6 . There 17 study visit , occur study entry every 2 week thereafter Day 70 ; Month 6 every 2 week thereafter Day 210 ; Months 9.5 , 12 , 18 , 24 , 30 , 36 . A physical exam , adverse event reporting , HIV pregnancy prevention counseling , medication history occur visit . Blood urine collection occur select visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV uninfected Has access participate HIV Vaccine Trials Unit ( HVTU ) willing follow duration study Willing receive HIV test result Good general health Willing use acceptable form contraception Completed least 12 year school ( South African participant ) HIV vaccine prior HIV vaccine trial Immunosuppressive medication within 168 day prior first study vaccine administration Blood product within 120 day prior first study vaccine administration Immunoglobulin within 60 day prior first study vaccine administration Live attenuate vaccine within 30 day prior first study vaccine administration Investigational research agent within 30 day prior first study vaccine administration Subunit kill vaccine within 14 day prior first study vaccine administration Current tuberculosis prophylaxis therapy Clinically significant medical condition , abnormal physical exam finding , abnormal laboratory result , past medical history may affect current health Any medical , psychiatric , social condition would interfere study . More information criterion find protocol . Any jobrelated responsibility would interfere study Serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Active syphilis infection Unstable asthma Diabetes mellitus type 1 2 Thyroid disease require treatment Serious angioedema within past 3 year Uncontrolled hypertension Bleeding disorder Cancer . If participant surgery remove cancer , opinion investigator , cancer likely recur study period , participant exclude . Seizure disorder Asplenia Mental illness would interfere compliance protocol Other condition , judgment investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>